SequelSEC

NovoCure Ltd NVCR

Surgical & Medical Instruments & Apparatus · CIK 0001645113 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$183.58M
Fiscal year ended 2026-06-30
Operating income
-$10.56M
Fiscal year ended 2026-06-30
Free cash flow
$1.22M
Fiscal year ended 2026-06-30

NovoCure Ltd (NVCR) reported revenue of $183.58M and net income of -$15.66M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from NovoCure Ltd’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

NovoCure Ltd income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$183.58M$174.06MUnavailable$167.20M$158.80M$154.99MUnavailable$155.10M$150.36M$138.50M
Cost of revenue$41.11M$38.93MUnavailable$44.73M$41.47M$38.52MUnavailable$35.37M$34.65M$33.69M
Gross profit$142.48M$135.13MUnavailable$122.48M$117.33M$116.47MUnavailable$119.72M$115.70M$104.81M
Operating income-$10.56M-$67.42MUnavailable-$36.02M-$39.52M-$37.86MUnavailable-$32.09M-$33.58M-$41.52M
Net income-$15.66M-$71.14MUnavailable-$37.27M-$40.14M-$34.32MUnavailable-$30.57M-$33.38M-$38.76M
Research & development$51.45M$58.34MUnavailable$54.03M$55.83M$53.78MUnavailable$51.88M$54.96M$51.60M
Weighted-average diluted sharesshares 116.01Mshares 114.15MUnavailableshares 111.91Mshares 111.57Mshares 110.28MUnavailableshares 108.25Mshares 107.70Mshares 107.27M
Pretax income-$12.45M-$69.26MUnavailable-$30.02M-$34.98M-$30.30MUnavailable-$21.58M-$22.73M-$31.64M
Income tax expense$3.21M$1.88MUnavailable$7.25M$5.16M$4.02MUnavailable$8.98M$10.65M$7.12M
Diluted EPS$-0.13$-0.62Unavailable$-0.33$-0.36$-0.31Unavailable$-0.28$-0.31$-0.36
Selling, general & administrative$101.59M$144.21MUnavailable$104.47M$101.02M$100.56MUnavailable$99.93M$94.33M$94.74M
General & administrative$39.91M$85.85MUnavailable$45.92M$43.96M$44.77MUnavailable$40.10M$37.71M$39.53M
Selling & marketing$61.68M$58.36MUnavailable$58.55M$57.07M$55.79MUnavailable$59.83M$56.62M$55.21M

Balance

NovoCure Ltd balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$93.70M$87.53MUnavailable$342.12M$149.62M$127.28MUnavailable$185.42M$164.80M$453.76M
Total assets$795.19M$787.93MUnavailable$1.36B$1.25B$1.25BUnavailable$1.22B$1.21B$1.12B
Current assets$638.52M$631.66MUnavailable$1.20B$1.08B$1.09BUnavailable$1.10B$1.09B$1.00B
Total liabilities$457.10M$457.21MUnavailable$1.02B$896.43M$886.85MUnavailable$861.20M$850.42M$762.07M
Current liabilities$220.71M$217.58MUnavailable$776.01M$749.63M$743.30MUnavailable$735.00M$169.18M$160.23M
Total equity incl. NCI$338.09M$330.72MUnavailable$341.33M$349.44M$361.96MUnavailable$360.78M$361.75M$359.36M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$42.22M$43.46MUnavailable$39.10M$40.21M$39.47MUnavailable$39.10M$40.44M$42.39M
Accounts receivable$99.13M$93.27MUnavailable$85.23M$89.92M$84.51MUnavailable$67.06M$64.70M$65.09M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$569.65M
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

NovoCure Ltd cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$8.13M-$13.52MUnavailable$20.57M-$15.94M-$35.66MUnavailable$10.38M-$1.72M-$31.57M
Capital expenditures$6.92M$5.15MUnavailable$5.66M$5.49M$10.61MUnavailable$10.68M$11.45M$11.78M
Investing cash flow-$6.38M$7.75MUnavailable$71.44M$35.99M-$6.47MUnavailable$10.19M-$374.44M$246.22M
Financing cash flow$4.55M-$166.00KUnavailable$100.52M$2.39M$5.25MUnavailable$100.00K$87.32M$213.00K
Net change in cash$6.29M-$6.07MUnavailable$192.50M$22.70M-$36.66MUnavailable$20.76M-$288.92M$214.80M
Stock-based compensation$17.01M$63.01MUnavailable$29.32M$26.14M$29.55MUnavailable$31.36M$31.83M$34.08M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$4.31M$4.12MUnavailable$3.66M$3.44M$3.32MUnavailable$2.46M$2.86M$2.82M

Derived

NovoCure Ltd derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow$1.22M-$18.67MUnavailable$14.92M-$21.42M-$46.28MUnavailable-$307.00K-$13.17M-$43.36M
Gross margin77.6%77.6%Unavailable73.2%73.9%75.1%Unavailable77.2%77.0%75.7%
Operating margin-5.8%-38.7%Unavailable-21.5%-24.9%-24.4%Unavailable-20.7%-22.3%-30.0%
FCF margin0.7%-10.7%Unavailable8.9%-13.5%-29.9%Unavailable-0.2%-8.8%-31.3%
SBC / revenue9.3%36.2%Unavailable17.5%16.5%19.1%Unavailable20.2%21.2%24.6%
Current ratio2.89x2.90xUnavailable1.55x1.45x1.47xUnavailable1.49x6.46x6.26x
Revenue YoY growth15.6%12.3%Unavailable7.8%5.6%11.9%Unavailable21.8%19.3%13.4%
Net margin-8.5%UnavailableUnavailable-22.3%-25.3%UnavailableUnavailable-19.7%UnavailableUnavailable
R&D / revenue28.0%33.5%Unavailable32.3%35.2%34.7%Unavailable33.5%36.5%37.3%
CapEx / revenue3.8%3.0%Unavailable3.4%3.5%6.8%Unavailable6.9%7.6%8.5%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NVCR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-23View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-24View SEC filing
10-Q · Filed 2025-04-24View SEC filing

Companies in the same industry

Reconciliation checks needing review

8 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2022-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2022-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.